Authors: WEISMAN MH BLUESTEIN HG BERNER CM DEHAAN HA

Citation: Mh. Weisman et al., REDUCTION IN CIRCULATING DSDNA ANTIBODY TITER AFTER ADMINISTRATION OFLJP-394, Journal of rheumatology, 24(2), 1997, pp. 314-318

Authors: WEISMAN MH BLUESTEIN HG

Citation: Mh. Weisman et Hg. Bluestein, A PILOT-STUDY OF LJP-394, A NOVEL THERAPEUTIC AGENT FOR THE TREATMENTOF SYSTEMIC LUPUS-ERYTHEMATOSUS, Arthritis and rheumatism, 38(9), 1995, pp. 896-896

Authors: BERLIT P MOORE PM BLUESTEIN HG

Citation: P. Berlit et al., VASCULITIS, RHEUMATIC DISEASE AND THE NEUROLOGIST - THE PATHOPHYSIOLOGY AND DIAGNOSIS OF NEUROLOGIC PROBLEMS IN SYSTEMIC-DISEASE, Cerebrovascular diseases, 3(3), 1993, pp. 139-145

Authors: SPEZIALETTI R BLUESTEIN HG PETER JB ALEXANDER EL

Citation: R. Spezialetti et al., NEUROPSYCHIATRIC DISEASE IN SJOGRENS-SYNDROME - ANTI-RIBOSOMAL-P AND ANTINEURONAL ANTIBODIES, The American journal of medicine, 95(2), 1993, pp. 153-160